IMMUNIC, INC. — Form 8-K
Filed September 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Form 8-K filed 2026-09-11 reports Item 5.02 events: departure of director(s) or officer(s) and appointment of certain officer(s), with associated compensatory arrangements. No specific names, dollar amounts, dates of departure, or compensation details are disclosed in the filing header or metadata provided; full details require examination of the complete 8-K document text.
Why this rating
Leadership changes are routine in biotech; lack of specifics prevents assessment. No financial amounts disclosed; relative to $83M market cap, impact unknown without details.
Extracted items
- 5.02 exec change
- 9.01 exhibits
See more from September 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.